5 takeaways from STAT’s investigation of the sprawling ‘three-parent IVF’ industry

STAT News has published a five-point summary of its investigation into the global fertility tourism industry, focusing on clinics that offer mitochondrial replacement therapy, commonly called “three-parent IVF,” to older women seeking to conceive.

According to STAT’s reporting, the procedure, originally developed and regulated for preventing transmission of mitochondrial disease, is being marketed in some clinics as a fertility treatment for age-related infertility, an application the investigation describes as unproven. The report traces how clinics operating outside stricter regulatory jurisdictions have built a sprawling, loosely governed industry around the procedure.

STAT’s takeaways outline the scope of this expansion, the regulatory gaps that allow it, and the experiences of patients who have traveled abroad to access the treatment. The investigation does not claim the procedure is unsafe outright, but characterizes its use for fertility purposes, rather than disease prevention, as lacking the evidentiary base that would normally support such offerings.

The piece situates this expansion within a broader pattern of fertility tourism, in which patients cross borders to obtain treatments unavailable or unapproved in their home countries. STAT frames the investigation as a window into how quickly a narrow, carefully regulated medical technique can be repurposed and commercialized once it moves beyond its original clinical and legal boundaries.

The full investigation and its five takeaways were published November 13.